What the Pfizer–HHS contract reveals
Newly released contract documents show that Pfizer has agreed to hand the U.S. Department of Health and Human Services a share of any net revenue it gains from charging higher drug prices abroad, according to reporting that drew on the filings. The provision sits inside the drugmaker's "most favored nation" agreement with the Trump administration and applies to medicines already on the market, running from Jan. 1, 2026 through Jan. 20, 2029. The rate of revenue sharing, the list of covered medicines and other commercial terms remain redacted in the released version of the contract. Public Citizen, the consumer watchdog that obtained the documents through a Freedom of Information Act lawsuit, released them on Saturday; documents covering a parallel agreement with Eli Lilly were disclosed at the same time, while more than two dozen other drugmaker deals remain confidential.
How the revenue-sharing clause is framed
White House spokesperson Kush Desai said the clause was designed so that "incremental revenue from higher prices abroad benefit American patients, not drugmakers," and added that "President Trump has been very clear that this is not a one-way street: Foreign prices are going to increase and American patients are no longer going to solely bear the burden of funding global innovation." Pfizer spokesperson Amy Rose said the company stands "by our belief that the agreement Pfizer voluntarily reached with the administration last September is a win for American patients" and described the deal as supporting lower prices for patients, redistributing global research and development costs and creating a more predictable investment environment. The contract states that any funds flowing to HHS will be "used for the purpose of lowering costs for US patients and taxpayers," but does not spell out how the money will be distributed or spent, leaving that question unresolved in the public record.
Linkage to U.S. trade negotiations
The release lands against a wider push by the administration to tie U.S. drug pricing to trade talks with other major pharmaceutical markets. A previously announced U.S.–U.K. arrangement allows tariff-free medicine imports in exchange for lower rebates paid by drugmakers to Britain's National Health Service, with the U.K. government set to increase spending on medicines by 25% under that arrangement. The contract for Pfizer is also tied to U.S. trade policy and offers more detail on how the higher foreign prices required under those talks would be channeled back to U.S. patients. Pfizer did not characterize the deal in its earlier White House fact sheet as revenue sharing, instead saying it "repatriate[s] increased foreign revenue on existing products that Pfizer realizes as a result of the President's strong America First U.S. trade policies for the benefit of American patients."
Share this article
